Medical Access and Reimbursement in Russia

Currently classified as a strictly controlled narcotic/psychotropic substance under the Russian federal controlled-substances listing, with no authorized medical use outside approved clinical research. Possession, manufacture or distribution is prosecuted under criminal law; exceptions require explicit authorization for scientific/medical research per the national controlled-substance lists. # #

Currently classified as a strictly controlled substance under Russian narcotics and psychotropic-substance control legislation, with no authorized therapeutic/medical access outside of tightly regulated clinical trials or explicit governmental authorizations. Standardized prosecution and criminal penalties apply for unauthorized possession, production or trafficking. #

Esketamine as the branded intranasal antidepressant (e.g., Spravato) does not have a recognized, reimbursed indication in routine Russian clinical practice and there is no evidence of routine regulatory registration/marketing authorization in the Russian drug registry for esketamine for depression; therefore it is not available as a reimbursed psychiatric therapy in the public system. Registration and marketing of new psychotropic medicinal products in Russia require authorization via the State Register of Medicines (GRLS) and central Ministry of Health processes; a widely used/approved esketamine antidepressant entry is not present in the GRLS registry search results available publicly. Use outside registration would be limited to formal clinical trials or exceptional import/compassionate pathways where permitted. # #

Ketamine is an approved, registered medicinal product in the Russian Federation for use as a general (non‑inhalational) anesthetic and analgesic and appears in national drug registries and essential-medicines listings; it is routinely used in hospitals and emergency medicine under standard medical licensing and prescribing rules. Registration entries and product dossiers for ketamine are present in the State Drug Registry (GRLS), and ketamine formulations are listed in government pharmaceutical information (GRLS entry indicates registration and inclusion in national lists). #

Medical/insurance context and reimbursement nuance: ketamine’s registered indications in Russia are for anesthesia and certain acute analgesic uses (as per product labeling), not for formal, licensed psychiatric indications such as treatment‑resistant depression; therefore any use of ketamine for psychiatric indications would be off‑label clinical practice. Public reimbursement (state-funded programs) covers officially registered indications and medicines included in the national list of vital and essential drugs (ЖНВЛП) or regional formularies; while some ketamine products are included in registries, off‑label psychiatric infusions or novel psychiatric protocols are not standard reimbursed services and, where applied, are conducted in private clinics or hospital settings with costs borne by the patient or negotiated locally. Practically: (1) Hospitals and licensed anesthesiology services use ketamine routinely for anesthesia/analgesia under standard procurement and reimbursement mechanisms; (2) Psychiatric/off‑label intravenous ketamine for depression is not a centrally reimbursed, guideline-endorsed program nationally and is effectively private/off-label. # #

Regional/state variability: procurement/reimbursement for registered anesthetic uses follows federal and regional health‑care budgeting; any institution-offered off‑label psychiatric ketamine protocols would depend on local hospital policy or private clinic pricing and are not uniformly covered by state insurance (OMS) across regions.

Currently classified as a strictly controlled narcotic/psychotropic substance in Russia (explicitly listed among controlled tryptamines and their derivatives), with no authorized medical use outside approved scientific research; possession, distribution or use outside authorized research or narrow legal exceptions is criminalized. National controlled-substance lists and implementing regulations identify DMT and its derivatives among prohibited substances. # #

Currently classified under Russian controlled‑substance law as a prohibited tryptamine derivative with no authorized medical use outside approved clinical research; access is limited to sanctioned scientific studies and any unauthorized possession/distribution is subject to criminal penalties. #

Not authorized as a medical product in routine Russian practice and functionally treated as a prohibited psychotropic/narcotic substance absent specific research authorization; there is no recognized, reimbursed therapeutic ibogaine program and any use would require formal research approvals and be exceptional. Currently there is no regulatory path in ordinary clinical practice for ibogaine therapy in Russia. # #

Ayahuasca preparations (which contain DMT) are treated under the same national controls as DMT and are effectively prohibited except where an explicit, narrow research or legal exemption applies; there is no lawful commercial or medically reimbursed ayahuasca therapy program in Russia. Possession, importation or distribution without authorization is penalized under narcotics legislation. # #

Mescaline and its cacti sources (where psychoactive mescaline is extracted) are controlled under Russian narcotics/psychotropic-substance lists and have no authorized therapeutic program or reimbursement outside approved scientific research; unauthorized possession or trafficking is criminalized. #

Substituted phenethylamines in the 2C family (2C‑X compounds) are explicitly controlled in Russia as part of the national lists of prohibited/controlled psychotropic substances; there is no authorized medical use or reimbursement pathway and access is restricted to properly authorized scientific research only. Unauthorized manufacture, sale or possession are prosecutable under criminal law. #